Home

Course of disease

Alzheimer's Disease

Read time: 3 min

Inside the black box: Unlocking the potential of big data in neurodegenerative diseases

Big data, artificial intelligence and machine learning offer huge opportunities for the collection...

Read time: 5 min

Managing the burdens of bipolar disorder

The cognitive and physiological burdens of bipolar disorder, and some approaches to its treatment,...

Alzheimer's Disease

Read time: 3 min

Congress highlights

It’s in the blood – identification of plasma biomarkers brings hope for screening and early detection of Alzheimer’s disease

The recent discovery and validation of blood biomarkers offers huge potential for the early...

Read time: 3 min

Congress highlights

Treating cognitive symptoms improves workplace productivity

The new paradigm for the treatment of major depressive disorder (MDD) is to “make patients...

Read time: 4 min

Congress highlights

Mechanisms underlying clinical manifestations of treatment resistance in schizophrenia

Antipsychotics are not effective in 30% of patients with schizophrenia. These patients have...

Parkinson's Disease

Read time: 3 min

Congress highlights

Managing strategies for Parkinson’s disease: A multipronged approach for a multifaceted illness

Parkinson’s disease is characterized by motor symptoms and a wide range of non-motor symptoms...

Read time: 3 min

Marking time: does lack of change raise more questions than answers?

We urgently need markers that reveal people’s risk of developing PD and, if they already have...

Bipolar, Schizophrenia

Read time: 4 min

Controversial issues in the management of schizophrenia

Controversial issues in the management of schizophrenia — brain shrinkage, dopamine...

Read time: 3 min

Data drives better categorization of patients

Subtypes of Parkinson’s Disease patients with different risks of progression – and...

Read time: 4 min

Neuronal vulnerability, not being neighbors, underlies synuclein spread

Post mortem evidence and connectome mapping show that the distribution of Lewy pathology does not...

Read time: 4 min

Schizophrenia – from prodrome to psychosis

Psychosis is preceded by a 3–4 year prodromal phase in 75% of patients, but only 25% of...

Depression, Schizophrenia

Read time: 1 min

How can you support carers for people with schizophrenia and psychosis?

More than 25.000 carers have already signed up to The Carer Academy, an interactive online course...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country